88 related articles for article (PubMed ID: 19758628)
1. A novel approach to using matrix metalloproteinases for bladder cancer.
Fernández CA; Wszolek MF; Loughlin KR; Libertino JA; Summerhayes IC; Shuber AP
J Urol; 2009 Nov; 182(5):2188-94. PubMed ID: 19758628
[TBL] [Abstract][Full Text] [Related]
2. Urinary biomarkers predict brain tumor presence and response to therapy.
Smith ER; Zurakowski D; Saad A; Scott RM; Moses MA
Clin Cancer Res; 2008 Apr; 14(8):2378-86. PubMed ID: 18413828
[TBL] [Abstract][Full Text] [Related]
3. Urine biomarkers may someday detect even distant tumors.
Schmidt C
J Natl Cancer Inst; 2009 Jan; 101(1):8-10. PubMed ID: 19116386
[No Abstract] [Full Text] [Related]
4. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.
Coticchia CM; Curatolo AS; Zurakowski D; Yang J; Daniels KE; Matulonis UA; Moses MA
Gynecol Oncol; 2011 Nov; 123(2):295-300. PubMed ID: 21889192
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
7. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Babjuk M
Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
[No Abstract] [Full Text] [Related]
9. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
10. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
11. Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Clin Cancer Res; 2001 Feb; 7(2):445-7. PubMed ID: 11234903
[No Abstract] [Full Text] [Related]
12. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
13. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
Fernández CA; Yan L; Louis G; Yang J; Kutok JL; Moses MA
Clin Cancer Res; 2005 Aug; 11(15):5390-5. PubMed ID: 16061852
[TBL] [Abstract][Full Text] [Related]
14. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
15. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
16. [Neutrophil gelatinase-associated lipocalin (NGAL): a biomarker beyond the confines of nephrology].
Bolignano D
G Ital Nefrol; 2010; 27(1):6. PubMed ID: 20191452
[No Abstract] [Full Text] [Related]
17. Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis.
Kim JW; Lee SH; Jeong SH; Kim H; Ahn KS; Cho JY; Yoon YS; Han HS
Tohoku J Exp Med; 2010 Dec; 222(4):319-27. PubMed ID: 21150136
[TBL] [Abstract][Full Text] [Related]
18. [Association between urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery].
Wan X; Cao CC; Chen Y; Xiao YL; Wu WF; Chen X; Mu XW
Zhonghua Yi Xue Za Zhi; 2008 May; 88(19):1318-22. PubMed ID: 18956700
[TBL] [Abstract][Full Text] [Related]
19. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
20. [Clinical implication of a novel biomarker Ngal in CKD].
Mori K; Mukoyama M; Kuwabara T; Kasahara M; Yokoi H; Nakao K
Nihon Rinsho; 2009 Jun; 67(6):1233-41. PubMed ID: 19507520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]